Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review[Formula presented]

Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Thomas B.L. Lam, Michael Lardas, Matthew Liew, Malcolm D. Mason, Muhammad Imran Omar, Olivier RouvièreIvo G. Schoots, Derya Tilki, Roderick C.N. van den Bergh, Theodorus H. van Der Kwast, Henk G. van Der Poel, Peter Paul M. Willemse, Cathy Y. Yuan, Badrinath Konety, Tanya Dorff, Suneil Jain, Nicolas Mottet, Thomas Wiegel

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

High-risk and locally advanced prostate cancer (PCa) patients are likely to undergo multimodality treatment. Patients should at all times be fully informed about all available options and the likelihood of a multimodal approach, including the potential side effects of both local and systemic treatment. For high-risk localized and locally advanced PCa, both radical prostatectomy as part as multimodal therapy and external beam radiotherapy (EBRT) + long-term androgen deprivation therapy (ADT) can be recommended as primary treatment. For high-risk localized PCa, EBRT + BT can also be offered despite a less favorable toxicity profile. In selected high-risk PCa patients, a shorter duration of ADT might be considered. Until the results of the SPCG15 trial are known, the optimal local treatment remains a matter of debate.

Original languageEnglish (US)
Pages (from-to)614-627
Number of pages14
JournalEuropean Urology
Volume77
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • Brachytherapy
  • External beam radiotherapy
  • Localized
  • Locally advanced
  • Modality treatment
  • Primary therapy
  • Prostate cancer
  • Radical prostatectomy
  • Systematic review
  • Systemic treatment

Fingerprint Dive into the research topics of 'Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review[Formula presented]'. Together they form a unique fingerprint.

  • Cite this

    Moris, L., Cumberbatch, M. G., Van den Broeck, T., Gandaglia, G., Fossati, N., Kelly, B., Pal, R., Briers, E., Cornford, P., De Santis, M., Fanti, S., Gillessen, S., Grummet, J. P., Henry, A. M., Lam, T. B. L., Lardas, M., Liew, M., Mason, M. D., Omar, M. I., ... Wiegel, T. (2020). Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review[Formula presented]. European Urology, 77(5), 614-627. https://doi.org/10.1016/j.eururo.2020.01.033